Are leukotrienes or PAF involved in hyperbaric oxygen toxicity?
Several very selective leukotriene inhibitors, and a PAF inhibitor, suitable forin vivo use, have been tested for their effects on hyperbaric oxygen toxicity.
The leukotriene D4 inhibitor, L660 771, and the 5-lipoxygenase pathway inhibitor L663 563, failed to affect convulsions or lung damage induced by hyperbaric oxygen (pressure range 515–615 kPa) in either rats or mice. The specific PAF antagonist L659 989 showed marginal protection against hyperoxic convulsions and did not alter pulmonary damage. The specific LTB4 antagonist SC-41930 was very effective in inhibiting hyperbaric oxygen-induced convulsions in both rats and mice. SC-41930 also very significantly protected rats against pulmonary oxygen toxicity, but had only marginally significant effects on pulmonary protection in mice.
KeywordsPathway Inhibitor Hyperbaric Oxygen LTB4 Lung Damage Oxygen Toxicity
Unable to display preview. Download preview PDF.
- D. Jamieson,Oxygen toxicity and reactive oxygen metabolites in mammals. Free Radical Biol. Med.7, 87–108 (1989).Google Scholar
- G. J. Dusting and A. G. Stewart,Overview of eicosanoid metabolism and relationship to platelet-activating factor. Reprod. Fertil. Dev.2, 417–421 (1990).Google Scholar
- S. E. Dahlen, J. Bjork, P. Hedqvist, K. E. Arfors, S. Hammarstrom, J. A. Lindgren and B. Samuelsson,Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivoeffects with relevance to the acute inflammatory response. Proc. Natl. Acad. Sci. USA,78, 3883–3891 (1981).Google Scholar
- J. Gillard, A. W. Fort-Hutchinson, C. Chan, S. Charleson, D. Denis, A, Foster, R. Fortin, S. Leger, C. S. McFarlane, H. Morton, H. Piechuta, D. Riendeau, C. A. Rouzer, J. Rokach, R. Young, D. E. MacIntyre, L. Peterson, T. Bach, G. Eiermann, S. Hopple, J. Humes, L. Hupe, S. Luell, J. Metzger, R. Meurer, D. K. Miller, E. Opas and S. Pacholok,L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol.67, 456–464 (1989).PubMedGoogle Scholar
- T. R. Jones, R. Zamboni, M. Belley, E. Champion, L. Charette, A. W. Ford-Hutchinson, R. Frenette, J-Y. Gauthier, S. Leger, P. Masson, C. McFarlane, H. Piechuta, J. Rokach, H. Williams, R. N. Young, R. N. DeHaven and S. S. Pong,Pharmacology of L-660,711 (MK-571): A novel potent and selective leukotriene D 4 receptor antagonist, Can. J. Physiol. Pharmacol.67, 17–28 (1989).PubMedGoogle Scholar
- M. M. Ponpipom, S.-B. Hwang, T. W. Doebber, J. J. Acton, A. W. Alberts, T. Biftu, D. R. Brooker, R. L. Bugianesi, J. C. Chabala, N. L. Gamble, D. W. Graham, M-H. Lam and M. G. Wu, (±)-Trans-2-(3-methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (L-659,989), a novel, potent PAF receptor antagonist. Biochem. Biophys. Res. Commun.150, 1213–1220 (1988).PubMedGoogle Scholar
- N. F. Voelkel, K. R. Stenmark, J. T. Reeves, M. M. Mathias and R. C. Murphy,Action of lipoxygenase metabolites in isolated rat lung. J. Appl. Physiol.57, 860–867.Google Scholar
- D. J. Fretland, D. L. Widomski, C. P. Anglin and T. S. Gaginella,The antiinflammatory agent SC-41930 inhibits granulocyte infiltration of the rodent dermis induced by 6-trans-leukotriene B 4. Prostaglandius Leukot. Essent. Fatty Acids44, 61–65 (1991).Google Scholar